Guardant Health, Inc.: directors' dealings · United States · SEC (Form 4)

About Guardant Health, Inc.

Guardant Health, Inc. is a U.S.-based precision oncology and liquid biopsy company listed on the NASDAQ under ticker GH. Headquartered in Palo Alto, California, in the United States, the company was founded in 2012 and has built a differentiated platform focused on using blood-based testing, tissue testing, clinical datasets, and AI analytics to help clinicians detect, characterize, and monitor cancer more effectively. It has become one of the best-known names in molecular diagnostics for oncology. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) Guardant’s business model is organized around three main pillars. The Oncology segment includes liquid and tissue-based genomic testing for patients with advanced and early-stage cancers. The Screening segment is centered on cancer screening, most notably Shield, the company’s blood test for colorectal cancer screening. The Biopharma & Data business monetizes real-world clinical-genomic data and related services for pharmaceutical partners, supporting drug development and the creation of companion diagnostics. Key products in the portfolio include Guardant360 Liquid, Guardant360 CDx, Guardant360 Tissue, Guardant Reveal, and Shield. ([about.guardanthealth.com](https://about.guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/?utm_source=openai)) From a competitive standpoint, Guardant Health is among the global leaders in liquid biopsy. Its edge comes from the scale and depth of its data assets, its scientific publication record, clinical adoption across major cancer centers, and its ability to move assays into FDA-cleared companion diagnostic roles and reimbursement pathways. The company stated in 2024 that it had surpassed 500 peer-reviewed publications featuring its technology, underscoring its scientific credibility in a highly competitive field. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) Recent milestones have been material. In January 2026, Guardant received additional FDA approvals for Guardant360 CDx, including in BRAF V600E-mutant metastatic colorectal cancer, and on May 4, 2026, in ESR1-mutated ER+/HER2- advanced breast cancer. In March 2026, Shield became more widely accessible through Quest Diagnostics’ national ordering and collection network. Guardant also announced a multi-year strategic collaboration with Merck in January 2026, reinforcing the company’s companion-diagnostics and smart-platform strategy. In its 2026 outlook, the company guided to full-year revenue of $1.25 billion to $1.28 billion. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx?utm_source=openai)) For investors in France, Belgium, and Switzerland, Guardant Health remains a growth-oriented healthcare name with strong strategic positioning, but it is still dependent on commercial execution, reimbursement expansion, and broader clinical adoption of blood-based cancer diagnostics on the NASDAQ market in the United States.